7 January 2020 - Analysis and insights from the November 2019 PBAC meeting.

Submissions

• 60 submissions were considered by the PBAC; 57 relate to the listing of a medicine, gene therapy, cellular therapy or medicinal preparation on the Pharmaceutical Benefits Scheme; the remaining three submissions relates to the listing of a vaccine on the National Immunisation Program
• 28 (47%) were major submissions
• 44 (73%) were initial submissions and 16 (27%) were resubmissions
• 14 (23%) submissions were for a ‘new (single entity) medicine’
• 18 (30%) submissions were for a cancer medicine
• 11 (18%) submissions included a CEA/CUA. The type of economic evaluation in some submissions is as yet unknown.
• One submission was withdrawn (erenumab, Aimovig)
• The PBAC considered five minor submissions that were not included in the published agenda

Outcomes

• The 60 submissions yielded 78 outcomes; 61 (78%) recommendations, 13 (17%) rejections & 4 (5%) deferrals. Insofar as some submissions included multiple requests; the number of outcomes exceeds the number of submissions.
• Only 4 (27%) of the 14 submissions for a new medicine were recommended
• The 18 submissions for a cancer medicine yielded 26 outcomes; 21 recommendations, 4 rejections and 1 deferral

Read outcomes from the November 2019 PBAC meeting

Looking for more insights? Contact us for a more detailed analysis of the outcomes from the November 2019 meeting.